Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rina-S vs Investigator's Choice in Platinum Resistant Ovarian Cancer
NCT06619236Phase 3Active, not recruiting
- Sponsor
- Genmab
- Start
- Feb 2025
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of rinatabart sesutecan in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Genmab. Primary endpoint: Progression-Free Survival at 1.5 years. Started Feb 2025; status: active, not recruiting.
02
Drugs
rinatabart sesutecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT06619236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619236.